Get informed when a big investor buys or sells
+ FollowOvervalued by 95.2% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $1.08 Billion |
|---|---|
| Enterprise Value | $1.01 Billion |
| Earnings per Share | $-1.89 |
| Beta | 1.41 |
| Outstanding Shares | 165,600,827 |
| P/E Ratio | -7.26 |
|---|---|
| PEG | 13.17 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1640.05 |
| Enterprise Value to EBIT | -13.31 |
| Enterprise Value to Net Income | -26 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas ...